Gary Gershony, MD
ASC PHYSCN DIPLOMATE
Medicine
School of Medicine

Dr. Gershony subsequently completed a fellowship in interventional cardiology at Emory University under the auspices of Dr. Andreas Grüntzig, the inventor of coronary and peripheral angioplasty. From 1994-1998 Dr. Gershony was Director of the Cardiac Catheterization Laboratories and Interventional Cardiology at the University of California, Davis, Medical Center. Following that he practiced interventional cardiology at John Muir Health Cardiovascular Institute in the San Francisco Bay Area where he was the Director of Cardiovascular Research, Education and Technology, and founded a successful Transcatheter Aortic Valve Replacement (TAVR) program starting in 2011. Dr. Gershony’s research interests include novel devices for complex coronary and peripheral angioplasty, transcatheter valve therapies and local drug-delivery to prevent restenosis. He has participated in numerous multi-center clinical trials as a Principal Investigator. Dr. Gershony has been board certified in general cardiology and interventional cardiology and is a Fellow of the American College of Cardiology, the Royal College of Physicians (Canada), the American Heart Association and the Society for Cardiovascular Angiography and Interventions. Dr. Gershony has authored over 100 manuscripts and abstracts in the field of cardiology and is a regularly invited faculty lecturer to the preeminent U.S. and international interventional cardiology meetings. Dr. Gershony has also served on the adjunct faculty of the Stanford Biodesign Program and is the author of 11 issued medical device patents. These patents led to the formation of two successful interventional cardiology companies (Vascular Solutions and AngioScore) that brought these innovative medical device technologies to widespread clinical use in the U.S. and internationally. Dr. Gershony joined the Division of Cardiology at UCSF in September of 2026.